Melanotan II (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Melanotan II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH) studied as an agonist at the melanocortin receptors, chiefly MC1R and MC4R. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 2.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, each 1 unit on a U-100 insulin syringe equals 0.01 mL and delivers 100 mcg, so a 1000 mcg (1 mg) dose is simply 10 units. This keeps the arithmetic clean across the low-microgram titration steps that characterise the published melanocortin work.

Standard (Gradual) Titration Schedule

The gradual loading schedule mirrors the slow dose-escalation approach used in the published model, where the daily microgram amount is stepped up roughly each week to manage nausea and flushing during the early phase before pigmentation responses appear.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 2.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Maintenance Schedule

Once a target pigmentation response is reached in the published model, the daily loading phase is replaced by intermittent maintenance dosing — far fewer injections per week to hold the effect rather than build it.

Supplies Needed

• Melanotan II vials (20 mg): ~2–3 vials for a full 8-week gradual loading run; ~1 vial covers an extended maintenance block at 1–2 injections weekly.
• Insulin syringes (U-100, 1 mL): ~56 for an 8-week daily loading schedule (one fresh syringe per draw); a handful per month during maintenance.
• Bacteriostatic water (10 mL): one bottle reconstitutes several 20 mg vials at 2 mL each.
• Alcohol swabs: a single 100-count box comfortably covers an 8-week loading schedule.

Protocol Overview

• Research goal: model melanocortin-receptor activation (MC1R/MC4R) and α-MSH-like pigmentation signalling.
• Schedule: daily subcutaneous loading, then 1–2× weekly maintenance in the published model.
• Dose band: 250–1000 mcg daily during loading; 500–1000 mcg per maintenance injection.
• Fill: 20 mg lyophilized, reconstituted to 10 mg/mL with 2 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 250 mcg step and hold each level for about a week before escalating.
• Early-phase nausea and flushing are most pronounced; slower titration reduces them in the published reports.
• Pigmentation responses in the model typically emerge only after several consecutive daily doses, not immediately.
• Shift to intermittent maintenance once the target response is reached rather than continuing daily dosing.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F) or below, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about one to two weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• The low microgram volumes here are small — measure carefully on a U-100 scale to avoid overdraw.
• Document each draw — date, volume, remaining material — for reproducibility.

How Melanotan II Works

Melanotan II is a synthetic cyclic heptapeptide modelled on α-melanocyte-stimulating hormone. It binds and activates several melanocortin receptors, most notably MC1R and MC4R. Stimulation of MC1R on melanocytes drives melanin synthesis and distribution, producing skin pigmentation independent of ultraviolet exposure in the research model. Its activity at MC4R — a receptor tied to appetite and sexual-arousal pathways in the central nervous system — accounts for the additional behavioural and appetite-related effects reported in the literature. The cyclic structure confers greater receptor affinity and metabolic stability than native α-MSH.

Reported Benefits & Side Effects

Benefits observed in research

• Increased skin pigmentation (tanning) without a requirement for UV exposure.
• Observable tanning responses after roughly 5–10 consecutive daily doses in the model.
• Reported induction of spontaneous erections in male subjects via MC4R activity.
• Intermittent maintenance dosing (1–2× weekly) reported to sustain pigmentation once established.

Side effects reported

• Common: nausea, facial flushing, reduced appetite, mild fatigue, spontaneous erections and injection-site reactions.
• Darkening or changes in moles and freckles have been noted.
• Serious: severe sympathomimetic symptoms and rhabdomyolysis have been reported at higher (≈6 mg) doses; the compound is not FDA-approved.

Injection Technique (Reference Only)

• Clean the vial stopper and the chosen site with alcohol swabs and let them dry.
• Use a 1 mL U-100 insulin syringe (29–31 gauge, ½-inch needle) for these small subcutaneous volumes.
• Pinch a skin fold roughly one inch thick and insert at a 45–90° angle depending on needle length.
• Do not aspirate for subcutaneous work; inject slowly, then rotate sites systematically.
• Dispose of used syringes immediately in an approved sharps container.

References

Related Protocols